|
1
|
García-Gómez C, Bianchi M, de la Fuente D,
Badimon L, Padró T, Corbella E and Pintó X: Inflammation, lipid
metabolism and cardiovascular risk in rheumatoid arthritis: A
qualitative relationship? World J Orthop. 5:304–311.
2014.PubMed/NCBI
|
|
2
|
Randolph GJ: Mechanisms that regulate
macrophage burden in atherosclerosis. Circ Res. 114:1757–1771.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ait-Oufella H, Sage AP, Mallat Z and
Tedgui A: Adaptive (T and B cells) immunity and control by
dendritic cells in atherosclerosis. Circ Res. 114:1640–1660. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Mangoni AA: Folic acid, inflammation, and
atherosclerosis: false hopes or the need for better trials? Clin
Chim Acta. 367:11–19. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Incalcaterra E, Accardi G, Balistreri CR,
Caimi G, Candore G, Caruso M and Caruso C: Pro-inflammatory genetic
markers of atherosclerosis. Curr Atheroscler Rep. 15:329–335. 2013.
View Article : Google Scholar
|
|
6
|
Raman K, Chong M, Akhtar-Danesh GG,
D’Mello M, Hasso R, Ross S, Xu F and Paré G: Genetic markers of
inflammation and their role in cardiovascular disease. Can J
Cardiol. 29:67–74. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Van-Assche T, Huygelen V, Crabtree MJ and
Antoniades C: Gene therapy targeting inflammation in
atherosclerosis. Curr Pharm Des. 17:4210–4223. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lu XT, Zhao YX, Zhang Y and Jiang F:
Psychological stress, vascular inflammation, and atherogenesis:
potential roles of circulating cytokines. J Cardiovasc Pharmacol.
62:6–12. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Martinet W, Schrijvers DM and De Meyer GR:
Molecular and cellular mechanisms of macrophage survival in
atherosclerosis. Basic Res Cardiol. 107:297–309. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Di Gregoli K and Johnson JL: Role of
colony-stimulating factors in atherosclerosis. Curr Opin Lipidol.
23:412–421. 2012.PubMed/NCBI
|
|
11
|
Chen LJ, Lim SH, Yeh YT, Lien SC and Chiu
JJ: Roles of microRNAs in atherosclerosis and restenosis. J Biomed
Sci. 19:79–92. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Schmerwitz UK, Sass G, Khandoga AG, et al:
Flavopiridol protects against inflammation by attenuating
leukocyte-endothelial interaction via inhibition of
cyclin-dependent kinase 9. Arterioscler Thromb Vasc Biol.
31:280–288. 2011. View Article : Google Scholar
|
|
13
|
Peng J, Zhu Y, Milton JT and Price DH:
Identification of multiple cyclin subunits of human P-TEFb. Genes
Dev. 12:755–762. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Licastro F, Candore G, Lio D, Porcellini
E, Colonna-Romano G, Franceschi C and Caruso C: Innate immunity and
inflammation in ageing: a key for understanding age-related
diseases. Immun Ageing. 2:82005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Stephens JW and Humphries SE: The
molecular genetics of cardiovascular disease: clinical
implications. J Intern Med. 253:120–127. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lipszyc PS, Cremaschi GA,
Zorrilla-Zubilete M, Bertolino ML, Capani F, Genaro AM and Wald MR:
Niacin modulates pro-inflammatory cytokine secretion. A potential
mechanism involved in its anti-atherosclerotic effect. Open
Cardiovasc Med J. 7:90–98. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Baumli S, Hole AJ, Wang LZ, Noble ME and
Endicott JA: The CDK9 tail determines the reaction pathway of
positive transcription elongation factor b. Cell. 20:1788–1795.
2012.PubMed/NCBI
|
|
18
|
Budhiraja S, Famiglietti M, Bosque A,
Planelles V and Rice AP: Cyclin T1 and CDK9 T-loop phosphorylation
are downregulated during establishment of HIV-1 latency in primary
resting memory CD4+ T cells. J Virol. 87:1211–1220.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang S and Fischer PM: Cyclin-dependent
kinase 9: a key transcriptional regulator and potential drug target
in oncology, virology and cardiology. Trends Pharmacol Sci.
29:302–313. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sunagawa Y, Morimoto T, Takaya T, et al:
Cyclin-dependent kinase-9 is a component of the p300/GATA4 complex
required for phenylephrine-induced hypertrophy in cardiomyocytes. J
Biol Chem. 285:9556–9568. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Garriga J and Grana X: Cellular control of
gene expression by T-type cyclin/CDK9 complexes. Gene. 337:15–23.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang Y, Liu XY and De Clercq E: Role of
the HIV-1 positive elongation factor P-TEFb and inhibitors thereof.
Mini Rev Med Chem. 9:379–385. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Marshall RM and Grana X: Mechanisms
controlling CDK9 activity. Front Biosci. 11:2598–2613. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Foskett SM, Ghose R, Tang DN, Lewis DE and
Rice AP: Antiapoptotic function of Cdk9 (TAK/P-TEFb) in U937
promonocytic cells. J Virol. 75:1220–1228. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Fu TJ, Peng J, Lee G, Price DH and Flores
O: Cyclin K functions as a CDK9 regulatory subunit and participates
in RNA polymerase II transcription. J Biol Chem. 274:34527–34530.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Marshall RM, Salerno D, Garriga J and
Grana X: Cyclin T1 expression is regulated by multiple signaling
pathways and mechanisms during activation of human peripheral blood
lymphocytes. J Immunol. 175:6402–6411. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kanazawa S, Okamoto T and Peterlin BM: Tat
competes with CIITA for the binding to P-TEFb and blocks the
expression of MHC class II genes in HIV infection. Immunity.
12:61–70. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Heidenreich S: Monocyte CD14: a
multifunctional receptor engaged in apoptosis from both sides. J
Leukoc Biol. 65:737–743. 1999.PubMed/NCBI
|
|
29
|
Herrmann CH, Carroll RG, Wei P, Jones KA
and Rice AP: Tat-associated kinase, TAK, activity is regulated by
distinct mechanisms in peripheral blood lymphocytes and
promonocytic cell lines. J Virol. 72:9881–9888. 1998.PubMed/NCBI
|
|
30
|
Miranda MB, Dyer KF, Grandis JR and
Johnson DE: Differential activation of apoptosis regulatory
pathways during monocytic vs granulocytic differentiation: a
requirement for Bcl-X(L)and XIAP in the prolonged survival of
monocytic cells. Leukemia. 17:390–400. 2003. View Article : Google Scholar
|
|
31
|
Xaus J, Cardo M, Valledor AF, Soler C,
Lloberas J and Celada A: Interferon gamma induces the expression of
p21waf-1 and arrests macrophage cell cycle, preventing induction of
apoptosis. Immunity. 11:103–113. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yang X, Gold MO, Tang DN, Lewis DE,
Aguilar-Cordova E, Rice AP and Herrmann CH: TAK, an HIV
Tat-associated kinase, is a member of the cyclin-dependent family
of protein kinases and is induced by activation of peripheral blood
lymphocytes and differentiation of promonocytic cell lines. Proc
Natl Acad Sci USA. 94:12331–12336. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Leitch AE, Lucas CD, Marwick JA, Duffin R,
Haslett C and Rossi AG: Cyclin-dependent kinases 7 and 9
specifically regulate neutrophil transcription and their inhibition
drives apoptosis to promote resolution of inflammation. Cell Death
Differ. 19:1950–1961. 2012. View Article : Google Scholar
|
|
34
|
Berberich N, Uhl B, Joore J, Schmerwitz
UK, Mayer BA, Reichel CA, Krombach F, Zahler S, Vollmar AM and
Furst R: Roscovitine blocks leukocyte extravasation by inhibition
of cyclin-dependent kinases 5 and 9. Br J Pharmacol. 163:1086–1098.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Johnson N and Shapiro GI: Cyclin-dependent
kinases (cdks) and the DNA damage response: rationale for cdk
inhibitor-chemotherapy combinations as an anticancer strategy for
solid tumors. Expert Opin Ther Targets. 14:1199–1212. 2010.
View Article : Google Scholar
|
|
36
|
Wang LM and Ren DM: Flavopiridol, the
first cyclin-dependent kinase inhibitor: recent advances in
combination chemotherapy. Mini Rev Med Chem. 10:1058–1070. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Krystof V, Baumli S and Furst R:
Perspective of cyclin-dependent kinase 9 (CDK9) as a drug target.
Curr Pharm Des. 18:2883–2890. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Sekine C, Sugihara T, Miyake S, Hirai H,
Yoshida M, Miyasaka N and Kohsaka H: Successful treatment of animal
models of rheumatoid arthritis with small-molecule cyclin-dependent
kinase inhibitors. J Immunol. 180:1954–1961. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Li L, Wang H, Kim Js, Pihan G and
Boussiotis V: The cyclin dependent kinase inhibitor (R)-roscovitine
prevents alloreactive T cell clonal expansion and protects against
acute GvHD. Cell Cycle. 8:1794–1802. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zoja C, Casiraghi F, Conti S, Corna D,
Rottoli D, Cavinato RA, Remuzzi G and Benigni A: Cyclin-dependent
kinase inhibition limits glomerulonephritis and extends lifespan of
mice with systemic lupus. Arthritis Rheum. 56:1629–1637. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Jia HY, Chen F, Chen JZ, Wu SS, Wang J,
Cao QY, Chen Z and Zhu HH: MicroRNA expression profiles related to
early stage murine concanavalin A-induced hepatitis. Cell Physiol
Biochem. 33:1933–1944. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Hou T, Ray S and Brasier AR: The
functional role of an interleukin 6-inducible CDK9.STAT3 complex in
human gamma-fibrinogen gene expression. J Biol Chem.
282:37091–37102. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Leitch AE, Haslett C and Rossi AG:
Cyclin-dependent kinase inhibitor drugs as potential novel
anti-inflammatory and pro-resolution agents. Br J Pharmacol.
158:1004–1016. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Galli SJ, Borregaard N and Wynn TA:
Phenotypic and functional plasticity of cells of innate immunity:
macrophages, mast cells and neutrophils. Nat Immunol. 12:1035–1044.
2011. View
Article : Google Scholar : PubMed/NCBI
|
|
45
|
Puga I, Cols M, Barra CM, et al: B
cell-helper neutrophils stimulate the diversification and
production of immunoglobulin in the marginal zone of the spleen.
Nat Immunol. 13:170–180. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
46
|
Gabrilovich DI and Nagaraj S:
Myeloid-derived suppressor cells as regulators of the immune
system. Nat Rev Immunol. 9:162–174. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Gordon V, Bhadel S, Wunderlich W, et al:
CDK9 regulates AR promoter selectivity and cell growth through
serine 81 phosphorylation. Mol Endocrinol. 24:2267–2280. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Li LL, Hu ST, Wang SH, Lee HH, Wang YT and
Ping YH: Positive transcription elongation factor b (P-TEFb)
contributes to dengue virus-stimulated induction of interleukin-8
(IL-8). Cell Microbiol. 12:1589–1603. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Smallie T, Ricchetti G, Horwood NJ,
Feldmann M, Clark AR and Williams LM: IL-10 inhibits transcription
elongation of the human TNF gene in primary macrophages. J Exp Med.
207:2081–2088. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Holgersen K, Kvist PH, Hansen AK and Holm
TL: Predictive validity and immune cell involvement in the
pathogenesis of piroxicam-accelerated colitis in interleukin-10
knockout mice. Int Immunopharmacol. 21:137–147. 2014. View Article : Google Scholar : PubMed/NCBI
|
